Background

One in five people in NSW suffers from chronic pain (defined as pain experienced every day for three months or more).1

Patients with chronic pain may present for treatment of:
- acute pain from unrelated injury or illness,
- exacerbation of chronic pain, or
- ongoing management of chronic pain.

These guidelines are intended to assist general practitioners (GPs) and other primary care clinicians to manage the complex medical, ethical and regulatory considerations involved in treating such patients, especially where there is exacerbation of chronic pain.

There are several published guidelines on the use of opioids in patients with chronic non-malignant pain.12 This document integrates the key points from these guidelines with practice-based experience from general practitioners, emergency physicians, pain specialists and others with expertise in this area. The recommendations are based on the best available evidence where such evidence has been identified, and the consensus views of experts where research evidence is lacking.

ISSUES IN MANAGEMENT

Goal of treatment

Management of chronic or recurrent non-malignant pain aims to enhance functioning (physical, psychological and social) and minimize distress. It should be possible to control pain to a tolerable level and maintain an acceptable level of function in social, occupational and personal life. It is rarely possible to completely eliminate chronic pain.

Pain is a subjective experience

Most cases of acute pain can be reliably attributed to an identifiable disease or damage process. By contrast, in chronic pain an identifiable process is less likely to be found. In addition to the obvious sensory dimension of pain (acute or chronic) there is an emotional component, which may include anxiety, depression, apprehension and fear. Particularly in chronic pain, where the link to obvious tissue damage may be unreliable, the emotional dimension may play a major role.

There is no objective test for pain; its assessment is always based on clinical judgement.


Multi-disciplinary approach to management

It is generally accepted that the management of chronic pain requires a multi-modality approach, which emphasises the role of non-drug techniques. Access to specialised health professionals (eg physiotherapists, psychologists) may be limited. Non-drug techniques can be utilised by doctors.

(See Box, page 3) Management should not rely on pharmacological therapy alone.

Pain management plan

A written pain management plan, agreed between patient, general practitioner and pain management team, is an important component of treatment. It helps general practitioners, Emergency Department physicians and locum practitioners provide consistent care. It also encourages patients to take an appropriate role in the management of their pain and helps them to deal with exacerbations that may occur out of normal business hours. Liaison between senior Emergency Department physicians and the general practitioner should occur as early as possible to identify and address the patient's beliefs and behaviours.

(Note: Psychosocial factors which may contribute to long-term disability ("yellow flags") are outlined in NSW TAG's Guidelines on Low Back Pain. See www.nswtag.org.au.)

Determining the appropriate opioid dose

When opioids are required, it is important that the appropriate dose is prescribed. The appropriate dose of an opioid analgesic is that which achieves satisfactory functioning with adequate pain control and tolerable side effects. Thus the closing decision requires clinical judgement. A common error is to use inadequate doses of opioid analgesics.
Management Principles

Aims of treatment:
- Control pain to a tolerable level (may not be possible to eliminate pain)
- Minimise distress
- Enhance functioning (physical, psychological, social)

Evaluation over time should include:
- Detailed pain history and assessment of impact of pain
- Psychosocial assessment
- Directed physical examination
- Review of previous diagnostic investigations
- Review of outcomes of previous interventions and strategies, including patient self-management
- Assessment of co-existing diseases/conditions

Management approach:
- Use both pharmacological and non-pharmacological modalities
  (see examples following)
- For more information on non-pharmacological modalities see NSW TAG’s Guidelines on Low Back Pain
- Assess regularly
- Use designated primary clinician
- Involve family and other supports
- Manage pain consistently in all settings, including ‘after hours’ attendances
- Encourage communication between primary clinician, Emergency Department and locum services
- Reassess: if analgesics not effective, discontinue and consider alternative management (see examples following)
- Refer to a multi-disciplinary pain clinic if appropriate and practical, and/or take advice from specialists by telephone if referral is impractical or delayed

Multi-disciplinary approach to chronic pain management

Multidisciplinary collaborations involving general practitioners and allied health professionals provide the best outcomes. Multidisciplinary pain programs emphasise a range of strategies:

<table>
<thead>
<tr>
<th>Strategy**</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Educate patient</td>
<td>Explain nature of chronic pain and relationship between mind and body, encourage realistic expectations, promote and support self-help, address beliefs</td>
</tr>
<tr>
<td>Prevent secondary dysfunction</td>
<td>Promote return to normal activity, encourage return to work, address fear avoidance behaviour</td>
</tr>
<tr>
<td>Optimise physical functioning</td>
<td>Encourage active physiotherapy/exercise</td>
</tr>
<tr>
<td>Enhance psychological well being</td>
<td>Use cognitive behavioural therapy, stress management, other psychological techniques</td>
</tr>
</tbody>
</table>

** For more information about strategies, see Nicholas et al, 2001

Levels of evidence

<table>
<thead>
<tr>
<th>Level</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level 1</td>
<td>Evidence obtained from systematic review of relevant randomised controlled trials</td>
</tr>
<tr>
<td>Level 2</td>
<td>Evidence obtained from one or more well-designed, randomised controlled trials</td>
</tr>
<tr>
<td>Level 3</td>
<td>Evidence obtained from well-designed, non-randomised controlled trials; or from well designed cohort or case control studies</td>
</tr>
<tr>
<td>Level 4</td>
<td>Opinions of respected authorities based on clinical experience, descriptive studies, reports of expert committees</td>
</tr>
</tbody>
</table>
Chronic Non-Malignant Pain:
Pharmacological Management and Rational Use of Opioids

- Use a step-wise approach.
- Use regular dosing rather than ‘as required’.
- Use maximal doses before moving to the next step.
- Assess response to medications after 2-3 weeks.
- If the patient does not respond, review and explore reasons for non-response.
- Consider combination therapy or addition of adjuvant medications. Choice of agents will depend on the diagnosis as well as pharmacological properties.
- Injectable opioids are rarely necessary. They should be reserved for patients with acute pain.
- Ideally, assessment by a pain clinic or consultation with a pain physician should precede the prescription of oral opioids.

### Step-wise Approach

<table>
<thead>
<tr>
<th>Step</th>
<th>Therapy</th>
<th>Comments</th>
<th>Painful disorders for which evidence of efficacy exists (see Note)</th>
<th>Level of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>First line: Non-opioid analgesics</strong></td>
<td>Paracetamol OR oral NSAID or topical NSAID</td>
<td>Use maximum doses before moving to the next step. Avoid NSAIDs, including COX-2 inhibitors, in patients who are volume depleted, elderly or have renal dysfunction. Avoid conventional NSAIDs in patients with a history of peptic ulcer disease.</td>
<td>Osteoarthritis (knee)</td>
<td>Level 2</td>
</tr>
<tr>
<td><strong>Second line: Combination therapy</strong></td>
<td>Paracetamol /NSAID or Paracetamol + codeine (fixed dose preparations) OR Tramadol</td>
<td>Use suppositories if oral therapy not tolerated. Coadministration is short-acting; place in long-term management of chronic pain is limited. Explain potential side effects (especially constipation).</td>
<td>Osteoarthritis (hip)</td>
<td>Level 2</td>
</tr>
</tbody>
</table>

**If pain is ongoing or involves neuropathic component**: Use low doses of tricyclics (eg amitriptyline up to 75mg at night). Trial of at least two weeks required. Anticonvulsants are useful in neuropathic pain but adverse effects are common.

| Third line: Strong opioids | Daycute SR (immediate release) 5-10mg every six hours | Assess after 24-48 hours, depending on clinical circumstances. Note that duration of action may be as short as 3 hours. Titrated dose and frequency to effect (efficacy and functioning). Use sustained release (SR) preparations in preference once effective daily dose has been determined. Reassess after 2-3 weeks. If response unsatisfactory, taper dose over several days and discontinue. Explain about potential physical dependence and other side effects (especially constipation). Benzodiazepines are not effective in managing pain. Combination with opioids potentiates adverse effects and increases risk of dependence. | Chronic low back pain, osteoarthritis, rheumatoid arthritis, fibromyalgia, postherpetic neuralgia, diabetic neuropathy | Level 1 |

### Painful disorders for which evidence of efficacy exits (see Note)

- Osteoarthritis (knee)
- Osteoarthritis, tendonitis
- Osteoarthritis (hip)
- Chronic back pain
- Chronic conditions including low back pain, joint conditions, neuropathic and orthopaedic pain
- Chronic low back pain, osteoarthritis, rheumatoid arthritis, fibromyalgia, postherpetic neuralgia, diabetic neuropathy
- Post-stroke pain
- Trigeminal neuralgia, diabetic neuropathy, post-herpetic neuralgia, post-stroke pain
- Chronic back pain

Note: Chronic pain is associated with a diverse range of conditions. It is not necessarily appropriate to extrapolate evidence from one condition to another. Levels of evidence in the table are annotated to explain the predominant conditions or conditions to which evidence relates. Evidence is generally based on short term studies (less than 6 weeks).
Injectable opioids in the management of chronic non-malignant pain

- The prescription of opioid injections is appropriate for management of acute injury or unrelated pain (eg trauma, myocardial infarction). However, it is inappropriate in patients presenting with an exacerbation of chronic pain. Repeated administration of opioids by injection increases the risk of dependence, infection and nerve damage.
- Use of opioids should be part of a planned treatment strategy, not the consequence of patient pressure.
- When patients claim intolerance of oral medication, this should be tested, if possible, in a supervised setting to ensure that they are not unnecessarily given drugs by injection.
- If an opioid injection is prescribed by a locum or Emergency Department practitioner, this should be brought to the attention of the primary practitioner as soon as possible.
- Patients should not be prescribed injectable medication for self-administration or administration by carers, except in very exceptional circumstances (eg terminal care).
- Use of injectable opioids in drug dependent patients who have an acute injury is not necessarily contraindicated, but requires careful consideration and supervision.
- In NSW (with some exceptions) if a patient is prescribed Schedule 8 drugs for periods in excess of 2 months, or if the patient is considered to be drug dependent, it is a legal requirement that authority for ongoing prescription be obtained from NSW Health Pharmaceutical Services Branch. This includes prescriptions for patients whose therapy has been initiated previously by another practitioner. Contact 02 9879 5239 for further information about authorities.

WHY PETHIDINE IS NOT RECOMMENDED

- Pethidine has a shorter duration of action than morphine with no additional analgesic benefit
- It has similar side-effects to morphine, including increased biliary pressure
- Pethidine is metabolised to norpethidine, which has potential toxic effects (eg convulsions), especially in patients with renal dysfunction.
- Pethidine is associated with potentially serious interactions in combination with other drugs.

Because of its euphoric effects:
- Pethidine is the drug most commonly requested by patients seeking opioids, and
- Pethidine is the drug most commonly abused by health professionals.

Use of opioids in patients known or suspected to be drug dependent

Patients known or suspected to be drug dependent may require treatment for pain. They have a right to have their pain managed in the same way as other patients, but management of their pain should be planned so that harm associated with drug dependence is minimised.

For clinical advice on the management of a patient with problems related to opioid dependence, call the NSW Drug and Alcohol Specialist Advisory Service on 1800 233 687 or 02 9557 2905. Doctors can call the Commonwealth Health Insurance Commission (HIC) on 1800 631 181 or the NSW HIC on 02 9895 3333 to check whether there is any information on a patient seeking benzodiazepines or opioids who may be seeing other doctors or obtaining multiple PBS prescriptions. However there are limitations to the value of such information (eg it may not be current or comprehensive).

Where drug-seeking behaviour is suspected (see box), doctors should usually refuse to prescribe opioids unless they believe they are clinically indicated or unless they feel that they will be putting themselves in danger by refusing.

Consultation with an expert in drug and alcohol management may be helpful. As usual, management decisions should be clearly documented. When a doctor refuses to prescribe opioids, it will usually be appropriate to refer the patient to a colleague experienced in drug and alcohol management. In some cases it may be desirable to refer the patient to hospital where they can be observed.

It is not appropriate to withhold analgesia from a patient who may be in genuine need of pain relief. Where the clinical situation is not clear despite investigation, and a decision needs to be made between prescribing or withholding opioid therapy, the worse error is to withhold analgesia.

DRUG SEEKING BEHAVIOUR should be suspected when a patient

- Seeks injectable rather than oral opioids, or steadily increasing dose
- Seeks repeated supply of opioids
- Insists on a specific medication and refuses alternatives
- Requests supplies of opioids in more than one form (eg oral and injectable)
- Requests opioids by name, particularly pethidine
- Gives a vague or evasive history or has atypical pain or non-anatomical distribution
- Has lack of accompanying signs (eg no haematuria in renal colic)
- Denies having a regular practitioner and cannot provide names of previous doctors
- Attends multiple practitioners (history of ‘Doctor Shopping’)
- Is non-compliant with suggested treatment
- In addition to requesting opioids, requests other ‘fashionable’ drugs (eg Polypen®/P)

None of these clues in isolation is completely reliable. Use professional judgement. A complete history and thorough examination are particularly important in such situations.
Management of acute pain in opioid dependent patients

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assess pain as usual.</td>
<td>Do not withhold opioid analgesia if clinically indicated.</td>
</tr>
<tr>
<td>Assess drug-seeking behaviour.</td>
<td>Make contact with previous prescriber(s) if possible. If undergoing methadone or buprenorphine treatment establish details of last dose, including time of administration. (Refer to NSW Health Department guidelines for methadone and buprenorphine maintenance treatment(^{23, 24}).)</td>
</tr>
<tr>
<td>Start with usual doses of opioids.</td>
<td>Opioid dependent patients will have greater tolerance to opioids and may have a lower pain threshold. Higher doses may be required at more frequent intervals. Consult with pain team if possible.</td>
</tr>
<tr>
<td>Reassess frequently and titrate dose to achieve adequate analgesia.</td>
<td>Where an organic cause for pain cannot be found, consider referral to a multi-disciplinary pain clinic.</td>
</tr>
<tr>
<td>Consider oral or parenteral NSAIDs or tramadol, especially if drug seeking behaviour is suspected.</td>
<td></td>
</tr>
</tbody>
</table>

Long-term management of patients who regularly use pethidine

Appropriate management of patients who regularly use pethidine will depend on patient circumstances. Most GPs will find it helpful to receive advice from a specialist pain physician and/or drug and alcohol physician and have access to back-up resources if required.

The following principles should form the basis of management:

- Patients should be strongly encouraged to use alternate pain management strategies. Young patients with an otherwise good prognosis and few concurrent conditions are likely to benefit from review and re-negotiation of their management plan. Patients with a long history of aberrant drug-related behaviour\(^{2, 3, 25}\) will be more difficult to manage and may not respond positively.

- Objectives of management must be clearly defined and agreed by both doctor and patient. As with other patients, the goal should be to control pain to a tolerable level and maintain an acceptable level of function in social, occupational and personal life.

- In a small proportion of patients, withdrawal from pethidine can be managed by GPs under close supervision and in consultation with a specialist in drug dependence. A staged approach is usually effective and involves:
  - As a brief intermediate step, transfer from parenteral to non-parenteral route of administration eg, intramuscular pethidine to oral pethidine (do not change drug of preference and route of preference at the same time).
  - Then transfer from oral pethidine to oral morphine.
  - Then transfer from high dose oral morphine to lower dose, then cease.

- At each stage, targets and achievements must be negotiated and agreed with the patient.
References


These guidelines were developed by the NSW Therapeutic Assessment Group Inc (NSW TAG). NSW TAG is an association of clinical pharmacologists, directors of pharmacy and other clinicians from the teaching hospitals in New South Wales. NSW TAG aims to investigate and establish therapeutic initiatives that foster high quality, cost-effective drug usage in the public hospitals of NSW and the wider community.

For further information contact:
NSW TAGE, PO Box 766 Darlinghurst NSW 2010,
Phone (02) 8382 2852/Fax (02) 9360 1005
Email: nswtag@stvincents.com.au
www.nswtag.org.au

A Steering Committee was established to advise on the development of these guidelines and the field review process. Committee membership included:

Dr Betty Chan, Emergency Physician, Prince of Wales Hospital
Professor Milton Cohen, Rheumatologist and Pain Physiologist, St Vincent's campus, Sydney
Mr Gabrielle Couch, Manager, Pharmacy Services, Southern Area Health Service
Professor Richard Day, Director, Clinical Pharmacology and Toxicology, St Vincent's Hospital
Ms Karan Gandecki, Principal Pharmaceutical Adviser, Pharmaceutical Services Branch, NSW Health
Dr Tony Giri, Clinical Director, Drug Programs Bureau, NSW Health
Ms Anna Grundy, Pharmacist, Emergency Department, Westmead Hospital
Dr Anna Holdgate, Deputy Director, Emergency Medicine, St George Hospital
Ms Karen Kaye, Executive Officer, NSW Therapeutic Assessment Group
Mr Margaret Knight, Consumer representative
Mr Andrew Leaver, Physiotherapist, Vice President, Australian Physiotherapy Association (NSW)
Mr Jeff McKee, Education and GA Program Manager, National Prescribing Service
Professor Andrea Mant, Area Adviser, Quality Use of Medicines Services, South East Health
Dr Alan Mitchley, Director, Cancer and Chronic Pain Clinic, Royal North Shore Hospital
Ms Wendy Rotem, Project Officer, NSW TAG
Dr Simon Wilcock, General Practice Unit, University of Sydney, Royal Australian College of General Practitioners
Dr Alex Worak, Alcohol and Drug Service, St Vincent's Hospital
Professor Nicholas Zwar, Director, Centre for Primary Care, University of New South Wales

NSW TAG acknowledges with thanks the assistance of individuals and organisations who provided comments and constructive suggestions during the field review process.